VanEck Pharmaceutical ETF
PPH
60 hedge funds and large institutions have $177M invested in VanEck Pharmaceutical ETF in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 19 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
26% more capital invested
Capital invested by funds: $141M → $177M (+$36.4M)
11.77% more ownership
Funds ownership: 40.69% → 52.45% (+12%)
3% more funds holding
Funds holding: 58 → 60 (+2)
8% less call options, than puts
Call options by funds: $419K | Put options by funds: $454K
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$39M |
| 2 |
Goldman Sachs
New York
|
+$17.1M |
| 3 |
VF
Virtu Financial
New York
|
+$2.42M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.27M |
| 5 |
LCM
LVM Capital Management
Portage,
Michigan
|
+$461K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.83M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$3.26M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.03M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.28M |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$2.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EDRS
51
Edmond de Rothschild (Suisse)
Geneva,
Switzerland
| $23K | +$12K | +200 | +100% |
|
|
WP
52
WealthPLAN Partners
Omaha,
Nebraska
| $22.9K | -$24K | -400 | -50% |
|
53
Simplex Trading
Chicago,
Illinois
| $15K | -$164K | -2,740 | -91% |
|
|
CFA
54
Carroll Financial Associates
Charlotte,
North Carolina
| $11K | – | – | – |
|
|
IA
55
IFP Advisors
Tampa,
Florida
| $9K | – | – | – |
|
|
WEC
56
Winslow Evans & Crocker
Boston,
Massachusetts
| $5.75K | – | – | – |
|
57
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $5K | – | – | – |
|
58
US Bancorp
Minneapolis,
Minnesota
| $4K | – | – | – |
|
|
AG
59
Advisor Group
Phoenix,
Arizona
| $3K | -$64K | -1,067 | -95% |
|
|
CI
60
Clal Insurance
Tel-Aviv,
Israel
| – | -$3.26M | -55,600 | Closed |
|
|
CS
61
Credit Suisse
Zurich,
Switzerland
| – | -$3.03M | -51,722 | Closed |
|
|
RJFSA
62
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$2.07M | -35,335 | Closed |
|
|
MA
63
Montag & Associates
Atlanta,
Georgia
| – | -$204K | -3,480 | Closed |
|
PPH Hedge Fund Activity: Q3 2016 in Review
60 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2016, worth a combined $177M — up 26% from $141M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PPH positions and 4 closed out — a net gain of 3 holders — while 13 added to existing stakes and 19 trimmed.
The largest buyer was Citigroup, adding an estimated $39M. The largest seller was Morgan Stanley, cutting an estimated $6.83M.
- 60 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2016, up from 58 in Q2 2016.
- Funds reported $177M of VanEck Pharmaceutical ETF stock for Q3 2016, up 26% quarter-over-quarter.
- 7 funds opened new VanEck Pharmaceutical ETF positions in Q3 2016 and 4 closed out, a net change of +3 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2016 was Citigroup, an estimated $39M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2016 was Morgan Stanley, an estimated $6.83M sold.
Based on aggregated 13F filings for Q3 2016.